semaglutide nejm weight loss New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Oral Semaglutide 25 mg and

846 Ferroptosis is present in the intestine during intestinal ischemia, along with increased expression of ACSL4 and decreased levels of FTH1 and GPX4, and inhibition of ACSL4 has protective effects on ferroptosis

Rather, they represent two sides of the same coin, interconnected through the intricate, bidirectional communication network known as the gut-brain axis

How does brain insulin resistance develop in Alzheimers disease

AhmadSFAnsariMANadeemABakheetSAAlzahraniMZAlshammariMAet al

Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events